About us

Dr. Franz von Nussbaum is a highly experienced MedChemist, with more than 20 years of experience in medicinal chemistry. He is the former VP Life Science Chemistry at Bayer AG and the current Executive VP at Nuvisan ICB.

Dr. Rainer Metternich is a Senior Executive (and former board member at Schering AG) with more than 30 years experience at global pharmaceutical companies and biotechs.

Professor Peter ten Dijke is a researcher and professor at Leiden University in the Netherlands. He is a distinguished expert in the field of molecular and cellular biology, with a focus on the regulation of gene expression and signaling pathways.

Prof. Dr. Oliver Koch is an expert in computational medicinal chemistry and molecular design. He's Professor of Computational Drug Discovery at the Institute of Pharmaceutical and Medicinal Chemistry and at the German Center of Infection Research.

Prof. Dr. Hans-Günther Schmalz is an expert in stereoselective and total synthesis. As a professor for Organic Chemistry at the University of Cologne, he initiated the academic research behind the ProM-approach together with Dr. Kühne.

Dr. Ronald Kühne is a highly experienced professional in Computational Chemistry and Drug Design. As the Head of Drug Design at the FMP in Berlin, he initiated the academic research behind the ProM-approach together with Prof. Dr. H.-G. Schmalz.

Mutlu Yönel is a seasoned finance and operations professional with a strong background in venture capital (built up the US office for E.ON SE) and extensive experience in management consulting.